Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Literature DB >> 30830874

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Alfred L Garfall, Edward A Stadtmauer, Wei-Ting Hwang, Simon F Lacey, Jan Joseph Melenhorst, Maria Krevvata, Martin P Carroll, William H Matsui, Qiuju Wang, Madhav V Dhodapkar, Kavita Dhodapkar, Rituparna Das, Dan T Vogl, Brendan M Weiss, Adam D Cohen, Patricia A Mangan, Emily C Ayers, Selene Nunez-Cruz, Irina Kulikovskaya, Megan M Davis, Anne Lamontagne, Karen Dengel, Naseem Ds Kerr, Regina M Young, Donald L Siegel, Bruce L Levine, Michael C Milone, Marcela V Maus, Carl H June.

Abstract

Entities: Disease Gene

Year: 2019 PMID： 30830874 PMCID： PMC6478404 DOI： 10.1172/jci.insight.127684

Source DB: PubMed Journal: JCI Insight ISSN： 2379-3708

Keyword Cloud
Cited

× No keyword cloud information.

12 in total

Review 1. Chimeric antigen receptor T-cell therapy for multiple myeloma.

Authors: Naoki Hosen
Journal: Int J Hematol Date: 2020-01-25 Impact factor: 2.490

Review 2. CAR T and CAR NK cells in multiple myeloma: Expanding the targets.

Authors: Urvi A Shah; Sham Mailankody
Journal: Best Pract Res Clin Haematol Date: 2020-01-13 Impact factor: 3.020

Review 3. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.

Authors: Mohamad Mohty; Jordan Gautier; Florent Malard; Mahmoud Aljurf; Ali Bazarbachi; Christian Chabannon; Mohamed A Kharfan-Dabaja; Bipin N Savani; He Huang; Saad Kenderian; Arnon Nagler; Miguel-Angel Perales
Journal: Leukemia Date: 2019-11-05 Impact factor: 11.528

4. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.

Authors: Jun Meng; XiaoQin Wu; Zhen Sun; RenDe Xun; MengSi Liu; Rui Hu; JianChao Huang
Journal: Front Oncol Date: 2021-07-26 Impact factor: 6.244

5. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.

Authors: Nina Shah; Jack Aiello; David E Avigan; Jesus G Berdeja; Ivan M Borrello; Ajai Chari; Adam D Cohen; Karthik Ganapathi; Lissa Gray; Damian Green; Amrita Krishnan; Yi Lin; Elisabet Manasanch; Nikhil C Munshi; Ajay K Nooka; Aaron P Rapoport; Eric L Smith; Ravi Vij; Madhav Dhodapkar
Journal: J Immunother Cancer Date: 2020-07 Impact factor: 13.751

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Review 1. Chimeric antigen receptor T-cell therapy for multiple myeloma.

Review 2. CAR T and CAR NK cells in multiple myeloma: Expanding the targets.

Review 3. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.

4. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.

5. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.

Review 6. Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma.

Review 7. BCMA-targeted immunotherapy for multiple myeloma.

Review 8. Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma.

Review 9. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.

Review 10. CAR T-Cells in Multiple Myeloma Are Ready for Prime Time.